MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Legend Biotech Corp ADR

Cerrado

SectorSanidad

33.29 5.75

Resumen

Variación precio

24h

Actual

Mínimo

30.96

Máximo

33.51

Métricas clave

By Trading Economics

Ingresos

161M

41M

Ventas

26M

187M

BPA

0.14

Margen de beneficios

21.719

Empleados

2,600

EBITDA

162M

52M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+164.47% upside

Dividendos

By Dow Jones

Próximas Ganancias

12 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-30M

6.4B

Apertura anterior

27.54

Cierre anterior

33.29

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Legend Biotech Corp ADR Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

13 may 2024, 11:36 UTC

Ganancias

Legend Biotech 1Q Loss Narrows with Higher Carvykti Sales

11 mar 2025, 11:09 UTC

Ganancias

Legend Biotech 4Q Research and Development Expenses $104.4M >LEGN

11 mar 2025, 11:08 UTC

Ganancias

Legend Biotech 4Q EPS 7c >LEGN

11 mar 2025, 11:00 UTC

Ganancias

Legend Biotech 4Q Rev $186.5M >LEGN

12 nov 2024, 12:06 UTC

Ganancias

Legend Biotech 3Q Loss/Shr 34c >LEGN

12 nov 2024, 12:05 UTC

Ganancias

Legend Biotech 3Q Net Trade Sales ABout $286M >LEGN

12 nov 2024, 12:00 UTC

Ganancias

Legend Biotech 3Q Rev $160.2M >LEGN

9 ago 2024, 11:02 UTC

Ganancias

Legend Biotech 2Q License Rev Was $90.8M >LEGN

9 ago 2024, 11:01 UTC

Ganancias

Legend Biotech 2Q Collaboration Rev $93.3M >LEGN

9 ago 2024, 11:01 UTC

Ganancias

Legend Biotech 2Q Loss/Shr 5c >LEGN

9 ago 2024, 11:00 UTC

Ganancias

Legend Biotech 2Q Rev $186.5M >LEGN

26 jul 2024, 11:01 UTC

Ganancias

Legend Biotech Expects 2H Adjusted Net Loss $94.7M

13 may 2024, 11:02 UTC

Ganancias

Legend Biotech 1Q Loss/Shr 16c >LEGN

13 may 2024, 11:02 UTC

Ganancias

Legend Biotech 1Q Research and Development Expenses $101.0M >LEGN

Comparación entre iguales

Cambio de precio

Legend Biotech Corp ADR previsión

Precio Objetivo

By TipRanks

164.47% repunte

Estimación a 12 Meses

Media 83.36 USD  164.47%

Máximo 95 USD

Mínimo 62 USD

De acuerdo con 15 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Legend Biotech Corp ADR Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

15 ratings

13

Comprar

2

Mantener

0

Vender

Puntuación técnica

By Trading Central

31.39 / 35.05Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Strong Bearish Evidence

Largo Plazo

Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Legend Biotech Corp ADR

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation operates as a subsidiary of Genscript Biotech Corporation.